Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand and sign the official consent form for the study
• People aged 18 or older at the time of signing the consent form
• People with a life expectancy of at least 3 months
• People with a good general level of physical functioning, as measured by a standard oncology scale (ECOG score of 0 or 1)
• People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer) confirmed by a tissue or cell sample — not the neuroendocrine or small cell types
• People whose prostate cancer has spread to other parts of the body, confirmed by CT scan, MRI, or bone scan
• People who are currently receiving hormone-blocking therapy (medical or surgical) to lower testosterone, or who have had both testicles surgically removed; those on medical therapy must continue it throughout the study
• People whose testosterone level is at or below castration level (50ng/dL or 1.7nmol/L) at the time of screening
• People whose cancer is continuing to grow or spread despite hormone-blocking treatment, shown by rising PSA levels, measurable disease progression on scans, or two or more new spots found on a bone scan
• People whose previous treatment history meets specific conditions depending on which part of the trial they are entering — including having had abiraterone acetate treatment that stopped working, and not having used certain newer hormone therapies (confirm with trial site for details on which group applies)
• People whose blood counts and organ function results are within acceptable ranges during screening
• People who agree to use effective contraception from the start of the study until at least 3 months after the last dose, and who agree not to donate sperm during this time
• People who are able to follow all the procedures required by the trial

Who may not be able to join:

• People who have previously taken certain newer androgen receptor-blocking medicines (such as enzalutamide, apalutamide, proxalutamide, or rezvilutamide), depending on which group of the trial is being considered (confirm with trial site for details)
• People who have previously received chemotherapy for castration-resistant prostate cancer (including antibody-drug conjugates)
• People who have previously been treated with an EZH2 inhibitor (such as tazemetostat or similar drugs)
• People who received most types of anti-cancer treatment within 4 weeks (or within 5 half-lives of the drug, whichever is shorter) before starting the trial, or palliative radiotherapy within 2 weeks before starting
• People who are planning to receive any other anti-cancer treatment during the trial
• People who took part in another clinical trial of an anti-cancer treatment within 28 days before starting, or whose last dose of a trial drug was within 28 days of starting this study
• People who have cancer that has spread to the brain or central nervous system
• People who have serious bone complications from cancer spread to the bones — such as poorly controlled severe bone pain, fractures in important locations, or spinal cord compression — that occurred in the past 6 months or are expected soon
• People who have had another type of cancer within the past 3 years that has not been considered clinically cured (some exceptions apply, such as certain treated skin cancers, superficial bladder cancer, breast ductal carcinoma in situ, and papillary thyroid cancer)
• People who have had a stroke or other serious brain blood vessel event within the past 12 months
• People who have reduced heart function or a serious heart condition
• People who have a severe active infection anywhere in the body
• People with a history of tuberculosis within the past year, or who had tuberculosis more than a year ago but did not receive adequate treatment for it
• People who are known to be allergic to the study drug or any of its ingredients
• People who have taken certain medicines that strongly affect how the body processes the study drug (moderate or strong CYP3A inducers or inhibitors) within 14 days before starting (confirm with trial site for the specific medicines involved)
• People with active autoimmune or inflammatory conditions such as lupus, rheumatoid arthritis, inflammatory bowel disease, or certain other conditions requiring ongoing systemic treatment (some managed conditions, such as controlled thyroid disease or skin conditions not needing systemic therapy, may be exceptions — confirm with trial site)
• People who have a history of interstitial lung disease, drug-related lung damage, or radiation-related lung inflammation that required steroid treatment, or who have any currently active lung inflammation of this type
• People with known significant gut or digestive problems that could affect how the body absorbs oral medicines, or who had an abdominal fistula, bowel perforation, or abdominal abscess within the past 6 months
• People who are HIV positive or have a positive syphilis test
• People with active hepatitis B or active hepatitis C infection, as determined by specific blood test results
• People who still have side effects from previous cancer treatment that have not resolved to a mild level (grade 1 or lower), unless the treating doctor considers the ongoing side effect acceptable for safety monitoring (such as hair loss)
• People with symptomatic fluid build-up around the lungs or heart that has not been controlled after multiple treatments
• People who have received an organ or tissue transplant from another person
• People who had major surgery within 4 weeks before starting the trial, or who have a major surgery planned during the study (minor procedures such as biopsies are generally permitted — confirm with trial site)
• People who received a live or live-attenuated vaccine within 28 days before starting the study (inactivated vaccines are permitted)
• People whose baseline bone scan shows a pattern called a "superscan" (an abnormal scan result — confirm with trial site)
• People whom the trial investigators consider unsuitable for the study for any other reason

Important: Always verify eligibility with the trial site directly before applying.